A Single arm, open label, phase II trial of tumour response to alectinib in patients with advanced tumours harbouring ALK gene alterations detected by comprehensive genomic profiling
Latest Information Update: 18 Apr 2022
At a glance
- Drugs Alectinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Oct 2021 Status changed from not yet recruiting to recruiting.
- 25 Mar 2021 New trial record